Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PLB 1004

Next Previous
X
Search
Drug Profile

PLB 1004

Alternative Names: PLB-1004

Latest Information Update: 30 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avistone Pharmaceuticals
  • Class Aniline compounds; Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 07 Aug 2024 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, First-line therapy) in China (PO) (NCT06574347)
  • 01 Jul 2024 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease) in USA (PO) (NCT06046495)
  • 28 Feb 2024 Avistone Biotechnology plans a phase III trial for Non small cell lung cancer (Late stage disease, Metastatic disease, First line therapy) in March 2024 (PO) (NCT06281964)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top